Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 29, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Darin T. Okuda, MD, and Karin Cook, who spoke about their research into the wasted costs associated with disease-modifying therapies for patients with multiple sclerosis and the wide-reaching impact of this waste on the healthcare continuum.
The NeurologyLive® team has been conducting interviews with thought leaders and covering the news on the latest updates in the clinical care of individuals with dementia including Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and others—and compiled it all in one place.
The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided context on the influence that genetics will have on drug development for Alzheimer disease in the coming years.
The professor of psychiatry and cell biology at NYU Langone provided insight on the reaction to a new paper that challenges how traditional drug development has approached Alzheimer disease. He discussed the flaws of current AD drug development, the need to transition away from antiamyloid agents, and why taking a pathogenetic approach can ease the concerns of those unsure of this new theory.
In episode 6 of this News Network series, Gabrielle Macaron, MD, shares her interpretation of the data and the importance of individualizing treatment for patients with multiple sclerosis.